Another extracellular signal pathway “PIP3 activates AKT signaling” is overrepresented only in HL and URF treatments, mainly due to upregulation of genes JUN, EGR1, CDKN1A, IER3, and HBEGF, whereas the enrichment of pathway “Dissolution of Fibrin Clot” is unique to HL treatment. The gene discussed is JUN; the disease is Hodgkins lymphoma.